The FDA will convene an advisory committee in September to review Grail's early cancer detection test, according to Endpoints News.
The timing is what makes this notable. Endpoints reports that the test failed to meet the primary endpoint of a large, randomized trial run in the UK, and describes the product as controversial.
A quick translation for non-specialists: the primary endpoint is the single main question a trial is designed to answer, chosen before the study begins precisely so a company can't go looking for a favorable result afterward. Missing it is the most consequential kind of failure a trial can have. A randomized trial — where participants are assigned by chance to be tested or not — is also the most rigorous format available, which makes a negative result hard to explain away.
An FDA advisory committee is a panel of outside experts the agency assembles when a product raises difficult questions. The panel reviews the data in a public session and votes on recommendations. The FDA is not obligated to follow that advice, though it frequently does. The practical effect is that the argument over Grail's evidence will be aired in the open rather than settled quietly in agency correspondence.
The Endpoints summary does not specify the trial's name or size, which endpoint was missed, or how Grail has responded — details that would sharpen the picture considerably.
Why it matters: tests that promise to catch cancer before symptoms appear are among the most closely watched products in medicine, and September's meeting will be a public test of how much evidence regulators require before such a test can be sold to patients.